0
0

Medication-Induced Movement Disorders and Other Adverse Effects of Medication

DOI: 10.1176/appi.books.9780890425596.805970

Sections

Excerpt

Medication-induced movement disorders are included in Section II because of their frequent importance in 1) the management by medication of mental disorders or other medical conditions and 2) the differential diagnosis of mental disorders (e.g., anxiety disorder versus neuroleptic-induced akathisia; malignant catatonia versus neuroleptic malignant syndrome). Although these movement disorders are labeled “medication induced,” it is often difficult to establish the causal relationship between medication exposure and the development of the movement disorder, especially because some of these movement disorders also occur in the absence of medication exposure. The conditions and problems listed in this chapter are not mental disorders.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

References

Addonizio G, Susman VL, Roth SD: Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 143(12):1587–1590, 1986
[PubMed]
 
Ananth J, Parameswaran S, Gunatilake S, et al: Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65(4):464–470, 2004
[PubMed]
 
Caroff SN: Neuroleptic malignant syndrome, in Neuroleptic Malignant Syndrome and Related Conditions, 2nd Edition. Edited by Mann SC, Caroff SN, Keck PEJr, Lazarus A. Washington, DC, American Psychiatric Publishing, 2003, pp 1–44
 
Caroff SN, Mann SC: Neuroleptic malignant syndrome. Psychopharmacol Bull 24(1):25–29, 1988
[PubMed]
 
Caroff SN, Mann SC: Neuroleptic malignant syndrome.Med Clin North Am 77(1):185–202, 1993
[PubMed]
 
Caroff SN, Mann SC, Keck PEJr, Francis A: Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20(2):257–259, 2000
[PubMed]
 
Gurrera RJ: Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 156(2):169–180, 1999
[PubMed]
 
Gurrera RJ, Caroff SN, Cohen A, Carroll BT, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72(9):1222–1228, 2011
[PubMed]
 
Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 155(8):1113–1116, 1998
[PubMed]
 
Keck PEJr, Pope HGJr, Cohen BM, et al: Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 46(10):914–918, 1989
[PubMed]
 
Mann SC, Caroff SN, Bleier HR, et al: Lethal catatonia. Am J Psychiatry 143(11):1374–1381, 1986
[PubMed]
 
Pope HGJr, Aizley HG, Keck PEJr, McElroy SL: Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry 52(5):208–212, 1991
[PubMed]
 
Rosebush PI, Mazurek MF: Serum iron and neuroleptic malignant syndrome. Lancet 338(8760):149–151, 1991
[PubMed]
 
Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 146(6):717–725, 1989
[PubMed]
 
Rosebush PI, Stewart TD, Gelenberg AJ: Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 50(8):295–298, 1989
[PubMed]
 
Sachdev P, Mason C, Hadzi-Pavlovic D: Case-control study of neuroleptic malignant syndrome.Am J Psychiatry 154(8):1156–1158, 1997
[PubMed]
 
Spivak B, Maline DI, Kozyrev VN, et al: Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry 15(5):330–333, 2000
[PubMed]
 
Strawn JR, Keck PEJr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 164(6):870–876, 2007
[PubMed]
 
Stübner S, Rustenbeck E, Grohmann R, et al: Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37(suppl 1):S54–S64, 2004
[PubMed]
 
Susman VL, Addonizio G: Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 176(4):234–241, 1988
[PubMed]
 
Velamoor VR, Norman RM, Caroff SN, Mann SC, et al: Progression of symptoms in neuroleptic malignant syndrome.J Nerv Ment Dis 182(3):168–173, 1994
[PubMed]
 
Yacoub A, Francis A: Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat 2(2):235–240, 2006
[PubMed]
 
Yamawaki S, Yano E, Uchitomi Y: Analysis of 497 cases of neuroleptic malignant syndrome in Japan. Hiroshima Journal of Anesthesia 26:35–44, 1990
 
Blier P, Tremblay P: Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 67(suppl 4):8–13, 2006
[PubMed]
 
Delgado PL: Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 67(suppl 4):22–26, 2006
[PubMed]
 
Demyttenaere K, Haddad P: Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand Suppl 403:50–56, 2000
[PubMed]
 
Fava M: Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 67(suppl 4):14–21, 2006
[PubMed]
 
Haddad PM: Antidepressant discontinuation syndromes. Drug Saf 24(3):183–197, 2001
[PubMed]
 
Haddad PM, Qureshi M: Misdiagnosis of antidepressant discontinuation symptoms. Acta Psychiatr Scand 102(6):466–467, 2000
[PubMed]
 
Kaymaz N, van Os J, Loonen AJ, Nolen WA: Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 69(9):1423–1436, 2008
[PubMed]
 
Mavissakalian MR, Perel JM: Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 56(9):821–827, 1999
[PubMed]
 
Schatzberg AF, Blier P, Delgado PL, et al: Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 67(suppl 4):27–30, 2006
[PubMed]
 
Shelton RC: The nature of the discontinuation syndrome associated with antidepressant drugs.J Clin Psychiatry 67(suppl 4):3–7, 2006
[PubMed]
 
Warner CH, Bobo W, Warner C, et al: Antidepressant discontinuation syndrome. Am Fam Physician 74(3):449–456, 2006
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation